Division of Pediatric Neurology, Department of Pediatrics, Mersin University School of Medicine, Mersin, Turkey.
Pediatr Neurol. 2012 Dec;47(6):423-6. doi: 10.1016/j.pediatrneurol.2012.08.003.
We investigated the mechanism of topiramate-related appetite loss and exposed its relationship to body weight, body mass index, body fat index, and serum insulin, lipid, leptin, neuropeptide-Y, cortisol, ghrelin, and adiponectin levels. Twenty children with epilepsy were evaluated at baseline and months 3 and 6 of treatment. Their body fat index, leptin, and neuropeptide-Y levels significantly decreased at month 3, whereas significant decreases occurred in body weight, body mass index, body fat index, neuropeptide-Y, cholesterol, and cortisol levels of patients at month 6 compared with baseline. Weight loss during topiramate treatment was attributed to loss of appetite and reduced food intake caused by reductions in neuropeptide-Y. To the best of our knowledge, this study is the first to describe reductions in neuropeptide-Y with topiramate use in humans.
我们研究了托吡酯相关食欲减退的机制，并揭示了其与体重、体重指数、体脂指数、血清胰岛素、脂质、瘦素、神经肽 Y、皮质醇、胃饥饿素和脂联素水平的关系。20 名癫痫患儿在基线和治疗 3 个月和 6 个月时进行评估。他们的体脂指数、瘦素和神经肽 Y 水平在第 3 个月显著下降，而与基线相比，患者的体重、体重指数、体脂指数、神经肽 Y、胆固醇和皮质醇水平在第 6 个月显著下降。托吡酯治疗期间的体重减轻归因于食欲下降和由于神经肽 Y 减少导致的食物摄入量减少。据我们所知，这项研究首次描述了人类使用托吡酯后神经肽 Y 的减少。
